Share Email Print

Proceedings Paper

Photoeradication and imaging of atheromatous plaque with texaphyrins
Author(s): Kathryn W. Woodburn; Fan Qing; David Kessel; Stuart W. Young
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Cardiovascular disease is the chief cause of death in the western world. Lutetium texaphyrin (PCI-0123) is a pure, synthetic, aqueous-soluble macrocycle that localizes in both cancerous lesions and atheromatous plaque. The lutetium texaphyrin complex is a potent photosensitizer in vivo, where it is activated by tissue-penetrating far red light (720 - 760 nm). Patient diagnosis and treatment planning are possible with PCI-0123 fluorescence imaging. In this study the localization and selective eradication of atheromatous plaque using PCI-0123 and photoangioplasty are discussed.

Paper Details

Date Published: 22 May 1997
PDF: 7 pages
Proc. SPIE 2970, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems VII, (22 May 1997); doi: 10.1117/12.275065
Show Author Affiliations
Kathryn W. Woodburn, Pharmacyclics, Inc. (United States)
Fan Qing, Pharmacyclics, Inc. (United States)
David Kessel, Wayne State Univ. School of Medicine (United States)
Stuart W. Young, Pharmacyclics, Inc. (United States)

Published in SPIE Proceedings Vol. 2970:
Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems VII
R. Rox Anderson; Kenneth Eugene Bartels; Lawrence S. Bass; Kenton W. Gregory; David M. Harris; Harvey Lui; Reza S. Malek; Gerhard J. Mueller; Michail M. Pankratov; Aaron P. Perlmutter; Hans-Dieter Reidenbach; Lloyd P. Tate; Graham M. Watson; Harvey Lui; Lawrence S. Bass; R. Rox Anderson; David M. Harris; Michail M. Pankratov; Kenneth Eugene Bartels; Lloyd P. Tate; Gerhard J. Mueller; Hans-Dieter Reidenbach; Graham M. Watson; Reza S. Malek; Aaron P. Perlmutter, Editor(s)

© SPIE. Terms of Use
Back to Top